Diabetic Med:使用医疗点HbA 1c测量来估计丹麦维堡市心血管筛查项目中67岁参与者中未确诊糖尿病的水平

2018-11-01 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于使用即时HbA 1c测量来估计丹麦维堡市心血管筛查项目中67岁参与者中未确诊糖尿病的水平的研究。以确定丹麦67岁老人参与针对心血管疾病和糖尿病的筛查计划中未识别糖尿病的患病率,并根据医疗点HbA 1c结合自我报告的糖尿病描述个体的血糖水平状态。 在这项以人口为基础的回顾性研究中,所有居住在维堡市的67岁人士都被邀请参加Vibor

近日,国际杂志 《Diabetic Med》上在线发表一项关于使用即时HbA 1c测量来估计丹麦维堡市血管筛查项目中67岁参与者中未确诊糖尿病的水平的研究。以确定丹麦67岁老人参与针对血管疾病和糖尿病的筛查计划中未识别糖尿病的患病率,并根据医疗点HbA 1c结合自我报告的糖尿病描述个体的血糖水平状态。

在这项以人口为基础的回顾性研究中,所有居住在维堡市的67岁人士都被邀请参加Viborg跨部门筛查计划(VISP),该计划的重点是心血管疾病和糖尿病。VISP研究于20148月开始,目前仍在进行中。在该计划的前两年,研究人员根据他们自我报告的糖尿病状态和单次HbA 1c测量将参与者分组。

本研究共有1802人接受邀请,1501人同意参与,其中7人因缺失数据(HbA 1c或糖尿病状态)被排除在外,最终参与率为82.9%(n = 1494)。在报告未患糖尿病的患者中,3.3%(n = 45)的HbA 1c水平≥48mmol/ mol6.5%)。在同一组中,16.7%(n = 226)的HbA 1c水平为41-48mmol / mol5.9-6.5%)。在自我报告的存在糖尿病患者中,30.1%(n = 43)的HbA 1c水平≥58mmol/ mol7.5%)。

基于单次HbA 1c测量,未确诊的糖尿病的患病率为3.3%。此外,16.7%报告未患糖尿病的人的HbA 1c水平为41-48 mmol / mol5.9-6.5%),代表了将成为患糖尿病风险增加的亚组。在自我报告的糖尿病患者中,30.1%的患者的HbA 1c水平≥58mmol/ mol7.5%),6.3%的患者的水平> 74 mmol / mol8.9%)。原始出处:

J. W. AndersenM. DahlK. B. Yderstraedeet al. Use of pointofcare HbA1c measurement to estimate the level of undiagnosed diabetes mellitus among 67yearold participants in a cardiovascular screening programme in the municipality of Viborg, Denmark

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970658, encodeId=6eb619e0658a8, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Aug 19 06:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803817, encodeId=11b7180381e6c, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Fri Dec 07 05:40:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638834, encodeId=aaee163883402, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 06 02:40:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760874, encodeId=38131e60874fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 21 10:40:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015939, encodeId=31e1201593987, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Apr 15 09:40:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609275, encodeId=fb0816092e5c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:40:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042003, encodeId=e499104200314, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:40:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1970658, encodeId=6eb619e0658a8, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Aug 19 06:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803817, encodeId=11b7180381e6c, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Fri Dec 07 05:40:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638834, encodeId=aaee163883402, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 06 02:40:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760874, encodeId=38131e60874fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 21 10:40:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015939, encodeId=31e1201593987, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Apr 15 09:40:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609275, encodeId=fb0816092e5c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:40:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042003, encodeId=e499104200314, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:40:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1970658, encodeId=6eb619e0658a8, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Aug 19 06:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803817, encodeId=11b7180381e6c, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Fri Dec 07 05:40:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638834, encodeId=aaee163883402, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 06 02:40:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760874, encodeId=38131e60874fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 21 10:40:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015939, encodeId=31e1201593987, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Apr 15 09:40:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609275, encodeId=fb0816092e5c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:40:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042003, encodeId=e499104200314, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:40:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1970658, encodeId=6eb619e0658a8, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Aug 19 06:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803817, encodeId=11b7180381e6c, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Fri Dec 07 05:40:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638834, encodeId=aaee163883402, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 06 02:40:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760874, encodeId=38131e60874fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 21 10:40:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015939, encodeId=31e1201593987, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Apr 15 09:40:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609275, encodeId=fb0816092e5c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:40:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042003, encodeId=e499104200314, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:40:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1970658, encodeId=6eb619e0658a8, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Aug 19 06:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803817, encodeId=11b7180381e6c, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Fri Dec 07 05:40:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638834, encodeId=aaee163883402, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 06 02:40:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760874, encodeId=38131e60874fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 21 10:40:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015939, encodeId=31e1201593987, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Apr 15 09:40:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609275, encodeId=fb0816092e5c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:40:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042003, encodeId=e499104200314, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:40:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2019-04-15 Smile2680
  6. [GetPortalCommentsPageByObjectIdResponse(id=1970658, encodeId=6eb619e0658a8, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Aug 19 06:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803817, encodeId=11b7180381e6c, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Fri Dec 07 05:40:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638834, encodeId=aaee163883402, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 06 02:40:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760874, encodeId=38131e60874fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 21 10:40:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015939, encodeId=31e1201593987, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Apr 15 09:40:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609275, encodeId=fb0816092e5c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:40:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042003, encodeId=e499104200314, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:40:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1970658, encodeId=6eb619e0658a8, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Aug 19 06:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803817, encodeId=11b7180381e6c, content=<a href='/topic/show?id=047ce594302' target=_blank style='color:#2F92EE;'>#筛查项目#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75943, encryptionId=047ce594302, topicName=筛查项目)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Fri Dec 07 05:40:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638834, encodeId=aaee163883402, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 06 02:40:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760874, encodeId=38131e60874fb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 21 10:40:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015939, encodeId=31e1201593987, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Apr 15 09:40:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609275, encodeId=fb0816092e5c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:40:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042003, encodeId=e499104200314, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:40:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Diabetic Med:临床检查和非侵入性筛查试验诊断糖尿病相关性足溃疡患者的外周动脉疾病

外周动脉疾病在糖尿病相关的足部溃疡患者中较为常见,并且是截肢的危险因素。检测或排除外周动脉疾病的最佳方法尚不明确。近日,国际杂志 《Diabetic Med》上在线发表一项关于临床检查和非侵入性筛查试验诊断糖尿病相关性足溃疡患者的外周动脉疾病的研究。本研究探讨了临床检查和非侵入性床旁检查在筛查糖尿病相关足部溃疡外周动脉疾病中的效用。本研究中约60人出现新发溃疡。对参与者进行脉冲,踝压,趾压,趾臂指

出现这8种腹痛,要谨慎对待!

一些腹痛基本特点的总结,但是临床上不能生搬硬套,需要根据患者临床表现和相关辅助检查综合判别。

产前超声诊断胎儿膈下隔离肺1例

孕妇33岁,孕1产0,因“孕24+2周产前超声检查发现胎儿腹部包块”就诊,无家族遗传病史。超声检查显示胎儿左肾上方肾上腺区见大小约2.1 cm×1.7 cm×1.5 cm高回声包块,类圆形,内部回声均匀,边界清晰,与肾上腺分界清(图1A)。CDFI示高回声包块内部供血动脉起源于腹主动脉(图1B)。超声诊断为膈下隔离肺。

弥漫性血管内凝血:检测和诊断

摘要:弥漫性血管内凝血(DIC)患者凝血系统异常是由高凝状态和纤溶亢进2种向量之和导致的。DIC根据两个向量的平衡状态分为纤溶亢进状态、高凝状态、大量出血或无症状型。脓毒血症相关的DIC患者的抗凝血酶(AT)和蛋白C(PC)的水平均显著下降,低水平的AT和PC活性分别造成凝血酶抑制物和活化Ⅷ因子的缺乏。凝血酶激活Ⅷ,而后活化的Ⅷ因子加速凝血途径形成凝血酶,因此凝血途径会持续被激活。日本医疗劳动福利

超声心动图诊断二尖瓣血性囊肿

患者女,50岁,因活动后胸闷、气促3年,加重1个月入院。体格检查:心率75次/分,律齐,血压130mmHg/70mmHg,胸骨左缘第3、4肋间可闻及4/6级收缩期吹风样杂音,心尖区可闻及3/6级收缩期杂音,未及心包摩擦音。心电图:窦性心律。术前经胸及术中经食道超声心动图检查:二尖瓣前瓣瓣尖(A2区)左心室侧可见一大小约2.3 cm×2.2 cm 的球形囊性肿块(图1),随心动周期在左心室与左心室流

RNA测序有助于遗传病的诊断

美国人类遗传学学会(ASHG)的年会于上周在圣地亚哥举行。会上公布的一项新研究表明,RNA测序有助于提高外显子组和基因组测序的遗传病诊断率。